Optimisation of itraconazole therapy using target drug concentrations

Clinical Pharmacokinetics

Volumn 35, Issue 6, 1998, Pages 461-473

  Poirier, Jean Marie ^a   Cheymol, Georges ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; BUSPIRONE; BUSULFAN; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DIDANOSINE; DIGOXIN; DRUG METABOLITE; FELODIPINE; HYDROXYITRACONAZOLE; ITRACONAZOLE; MEVINOLIN; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PLASMA PROTEIN; RIFAMPICIN; TERFENADINE; TRIAZOLAM;

AREA UNDER THE CURVE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DYSPEPSIA; FOOD INTAKE; GASTROINTESTINAL DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIPOPHILICITY; LIVER METABOLISM; MYCOSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; VERTIGO;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG MONITORING; FOOD-DRUG INTERACTIONS; HUMANS; ITRACONAZOLE; ORGAN SPECIFICITY;

EID: 0032438509     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199835060-00004     Document Type: Review

References (59)

1. Joly V, Yeni P. Antifongiques: données générales. In: Carbon C, Regnier B, Saimot G, et al. Médicaments anti-infectieux. Paris: Médecine Sciences Flammarion, 1994: 449-53
2. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-44
3. Odds FC, Vranckx L, Woestenborghs F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 1995; 39: 2051-60
4. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997; 24: 235-47
5. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988; 32: 1310-3
6. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 Suppl. 1: 67-87
7. Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997; 50: 477-80
8. Gorlero F, Larosa E, Cauwenbergh G, et al. Itraconazole plasma and vaginal mucosal levels in patients with chronic vaginal candidosis treated with itraconazole 200 mg once daily for 3 consecutive days. Drug Invest 1993; 6: 22-4
9. Schäter-Korting M, Korting HC, Lukacs A, et al. Levels of itraconazole in skin blister fluid after a single oral dose during repetitive administration. J Am Acad Dermatol 1990; 22: 211-5
10. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993; 37: 778-84
11. Zimmermann T, Yeates RA, Laufen H, et al. Influence of concomitant food intake on oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147-50
12. Van de Velde VJ, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16: 424-8
13. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin 1997; 52: 235-7
14. Boelaert J, Schurgers M, Matthys E, et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988; 32: 1595-7
15. Coronel B, Persat F, Dorez D, et al. Itraconazole concentrations during continuous haemofiltration. J Antimicrob Chemother 1994; 34: 448-9
16. Arredondo G, Martinez-Jorda R, Calvo R, et al. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther 1994; 32: 361-4
17. Smith D, Van de Velde V, Woestenborghs R, et al. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992; 44: 618-9
18. Lazo de la Vega S, Volkow P, Yeates RA, et al. Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. Drugs Under Exper Clin Res 1994; 20: 69-75
19. May DB, Drew RH, Yedinak KC, et al. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994; 14: 509-13
20. Tucker RM, Denning DW, Hanson H, et al. Interaction of azoles with rifampin, phenytoin and carbamazepine: in vitro and clinical observations Clin Infect Dis 1992; 14: 165-74
21. Bonay M, Jonville-Bera AP, Diot P, et al. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993; 9: 309-11
22. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more then ten fold by phenytoin. Clin Pharmacol Ther 1995; 58: 617-24
23. Partanen J, Jalava KM, Neuvonen PJ. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol 1996; 79: 274-6
24. Pohjola Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increase risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45; 191-3
25. McLachlan AJ, Tett SE. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. Ther Drug Monit 1998; 20: 390-5
26. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. Anticancer Res 1996; 16 (4A): 2083-8
27. Olkkola KT, Backman JT, Neunoven PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-5
28. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is a potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-7
29. Kivisto KT, Lamberg TS, Kantola T, et al. Buspirone concentrations are greatly increased by erythromycin and itraconazole. Eur J Clin Pharmacol 1997; 52 Suppl.: A 134
30. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61
31. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410-5
32. 2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal [abstract]. Br J Clin Pharmacol 1988; 27: 105P-6
33. McClean KL, Sheelan GJ. Interaction between itraconazole and digoxin. Clin Infect Dis 1994; 18: 259-60
34. Warnock DW, Turner A, Burke J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother 1988; 21: 93-100
35. Hosteller JS, Heykants J, Clemons KV, et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993; 37: 2224-7
36. Woestenborghs R, Lorreyne W, Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chronmatography. J Chromatogr 1987; 413: 332-7
37. Poirier JM, Lebot M, Descamps P, et al. Determination of itraconazole and its active metabolite in plasma by column liquid chromatography. Ther Drug Monit 1994; 16: 602-7
38. Compas D, Touw DJ, de Goede PN. Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography. J Chromatogr Biomed Appl 1996; 687: 453-6
39. Poirier JM, Cheymol G. A rapid and specific liquid chromatographic assay for the determination of itraconazole and hydroxyitraconazole in plasma. Ther Drug Monit 1947; 19: 247-8
40. Brandsteterova E, Kubalec P, Rady A, et al. Determination of itraconazole and its metabolite using SPE-HPLC. Pharmazie 1995; 50: 597-9
41. Lacroix C, Wojciechowski F, Danger P. Simultaneous determination of itraconazole, hydroxy-itraconazole and amphotericin B in human plasma by HPLC with photodiode array detection. Ann Biol Clin 1995; 53: 293-7
42. Poirier JM, Hardy S, Isnard F, et al. Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dose regimen. Ther Drug Monit 1997; 19: 525-9
43. Berenguer J, Ali NM, Allende MC, et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303-8
44. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma concentrations. Mycoses 1989; 32 Suppl. 1: 103-8
45. Tricot G, Joosten E, Boogaerts MA, et al. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomised studies. Rev Infect Dis 1987; 9 Suppl. 1: S94-99
46. Bradford CR, Prentice AG, Warnock DW, et al. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblaslic leukaemia. J Antimicrob Chemother 1991; 28: 555-60
47. Persat F, Marzullo C, Guyotat D, et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992; 28 (A): 838-41
48. Petropoulou T, Liese J, Tintelnot K, et al. Long-term treatment of patients with chronic granulomatous disease (CGD) for prophylaxis against Aspergillus infections [in German]. Mycoses 1994; 37 Suppl. 2: 64-9
49. Prentice AG, Warnock DW, Johnson SAN, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995; 36: 657-63
50. Poirier JM, Berlioz F, Isnard F, et al. Marked intra- and interpatient variability of itraconazole steady state plasma concentrations. Therapie 1996; 51: 163-7
51. Levron JC, Le Moing, Chwetzoff E. Exemple of active therapeutic drug monitoring: itraconazole [in French]. Therapie 1996; 51: 502-6
52. Eichel M, Just-Nübling G, Helm EB, et al. Itraconazole suspension in the treatment of HIV-infected patients suffering from fluconazole-resistant oropharyngeal and oesophageal candidosis [in German]. Mycoses 1996; 39 Suppl. 1: 102-6
53. Reynes J, Bazin C, Ajana F, et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother 1997; 41: 2554-8
54. Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996; 51: 585-620
55. Prentice AG, Warnock DW, Johnson SAN, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994; 34: 247-52
56. Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safely of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997; 41: 2714-8
57. Graybill JR. Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect 1994; 28 Suppl. 1: 17-24
58. British Society for Antimicrobial Chemotherapy Working Party. Laboratory monitoring of antifungal chemotherapy. Lancet 1991; 337: 1577-80
59. Working Party of the British Society for Antimicrobial Chemotherapy. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. J Antimicrob Chemother 1943; 32: 5-21